

1 **Cell proliferation effects of *S*-allyl-L-cysteine are associated with phosphorylation of**
2 **Janus kinase 2, insulin-like growth factor type-I receptor tyrosine kinase, and**
3 **extracellular signal-regulated kinase 2 in primary cultures of adult rat hepatocytes**

4

5 Hajime Moteki,* Masahiko Ogihara, and Mitsutoshi Kimura

6

7 *Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Josai*
8 *University; 1-1 Keyakidai, Sakado City, Saitama 350-0295, Japan*

9

10 *Correspondence: Department of Clinical Pharmacology, Faculty of Pharmaceutical
11 Sciences, Josai University; 1-1 Keyakidai, Sakado City, Saitama 350-0295, Japan.

12 Tel/Fax: +81-049-271-8078, E-mail: hmoteki@josai.ac.jp

13

14

15

16

17

18

19

20

21

22

23

24

25 **Abstract**

26 The cell proliferation effect of *S*-allyl-L-cysteine (SAC) and its mechanisms were
27 examined in primary cultures of adult rat hepatocytes. In serum-free cultivation, SAC (10^{-6}
28 M)-stimulated hepatocytes showed significant proliferation compared to control at 5-h
29 culture; the effect was dependent on the culture time and the dose of SAC (EC_{50} value
30 8.58×10^{-8} M). In addition, SAC-stimulated hepatocytes significantly increased mRNA
31 expression levels of *c-Myc* and *c-Fos* at 1 h and *cyclin B1* at 3.5 and 4 h, respectively. In
32 contrast, alliin and allicin, structural analogs of SAC, did not show these effects observed
33 with SAC. The SAC-induced hepatocyte proliferation effects were completely suppressed
34 by monoclonal antibodies against growth hormone receptor and insulin-like growth factor
35 type-I (IGF-I) receptor, respectively. Furthermore, the Janus kinase 2 (JAK2) inhibitor
36 TG101209, phospholipase C (PLC) inhibitor U-73122, IGF-I receptor tyrosine kinase
37 (RTK) inhibitor AG538, PI3 kinase inhibitor LY294002, MEK inhibitor PD98059, and
38 mTOR inhibitor rapamycin completely suppressed the SAC-induced hepatocyte
39 proliferation. JAK2 (p125 kDa) phosphorylation in cultured hepatocytes peaked 5 min
40 after SAC stimulation. SAC-induced IGF-I RTK (p95 kDa) and ERK2 (p42 kDa)
41 phosphorylation had slower rises than JAK2, peaking at 20 and 30 min, respectively.
42 These results indicate that SAC promoted cell proliferation by growth hormone
43 receptor/JAK2/PLC pathway activation followed by activation of the IGF-I
44 RTK/PI3K/ERK2/ mTOR pathway in primary cultures of adult rat hepatocytes.

45

46 **Keywords**

47 *S*-Allyl-L-cysteine (SAC), proliferation, Janus kinase 2 (JAK2), Insulin-like growth
48 factor type I (IGF-I), Extracellular signal-regulated kinase 2 (ERK2)

49 **1. Introduction**

50 The liver has a self-regenerative function called liver regeneration, which causes rapid
51 regeneration following liver damage or surgical resection (Fausto, 2000; Michalopoulos
52 and DeFrances, 1997). The mitogen-activated protein (MAP) kinase pathway is a series
53 of phosphorylation cascade reactions induced by the activation of receptor tyrosine kinase
54 (RTK) during liver regeneration. This pathway ultimately activates a serine/threonine
55 kinase called extracellular signal-regulated kinase (ERK) that promotes cell proliferation
56 and differentiation (Fausto et al., 2006; Morrison, 2012).

57 *S*-Allyl-L-cysteine (SAC) is a water-soluble compound in which an allyl group is
58 bonded to the sulfur atom of cysteine. SAC is contained in a minuscule quantity in fresh
59 garlic, but its content increases up to about 36 times during aging of garlic for 3 months
60 (Colín-González et al., 2012). In the garlic aging process, SAC is biosynthesized from γ -
61 glutamyl-S-allyl cysteine by a γ -glutamyl transferase. The synthesized SAC is oxidized
62 to alliin (*S*-allyl-L-cysteine sulfoxide), and it is hydrolyzed to allyl sulfenic acid
63 (Borlinghaus et al., 2014; Colín-González et al., 2012). Allicin (diallylthiosulfinate) is
64 produced by the condensation of this allyl sulfenic acid (Fig. 1). There is also a pathway
65 in which alliin and allicin are synthesized without going through SAC (Amagase et al.,
66 2001).

67 Extracted substances of aged garlic and SAC have an antioxidant effect based on the
68 removal of active oxygen or activation of nuclear factor-erythroid 2-related factor 2
69 (Nrf2) (Colín-González et al., 2015, 2012; Kalayarasan et al., 2008). Therefore, SAC is
70 used as a supplement in Japan because it is effective for hypertension and
71 hypercholesterolemia (Colín-González et al., 2012; Kim et al., 2006; Sohn et al., 2012).
72 In addition, pharmacological effects of SAC other than these are becoming clear, and one

73 of them is a cell proliferation effect. For example, SAC has been demonstrated to promote
74 neuroblast division and differentiation by increasing the expression of serotonin 5-HT_{1A}
75 receptors in the dentate gyrus of mice (Nam et al., 2011). Furthermore, we have
76 previously reported that SAC, but not *S*-methyl-L-cysteine or cysteine, accelerated liver
77 regeneration by promoting DNA synthesis in remnant liver and restoring liver function in
78 two-thirds partially hepatectomized rats (Kurihara et al., 2020). However, it is not clear
79 by what mechanism of action SAC exerts a cell proliferation-promoting effect on hepatic
80 parenchymal cells.

81 The aim of this study was to examine the detailed signal transduction pathways of cell
82 proliferation induced by SAC in primary cultures of adult rat hepatocytes. Thus, the cell
83 proliferation effect of SAC was compared to that of alliin or allicin by measuring the
84 number of hepatocyte nuclei, the progression of S-phase (DNA synthesis phase) in the
85 cell cycle, and the expression levels of genes, such as *c-Myc*, *c-Fos*, and *cyclin B1*
86 associated with liver regeneration. Moreover, the activity of growth-related signaling
87 elements such as RTK or MAPK involved in hepatocyte proliferation was measured using
88 various inhibitors of SAC-induced cell proliferation, and the mechanism of SAC on cell
89 proliferation in primary cultured hepatocytes was considered.

90

91 **2. Materials and Methods**

92 **2.1 Animals**

93 Male Wistar rats weighing 180-200 g were obtained from Sankyo Labo Service Corp.
94 (Tokyo, Japan). The pre-experimental acclimatization was set for 3 days, and during this
95 period, rats had *ad libitum* access to food and water. The handling of all rats used in this
96 study complied with the Guidelines for the Care and Use of Laboratory Animals of Josai

97 University (Nos. JU 20035 and JU 21035).

98

99 **2.2 Isolation and culture of hepatocytes**

100 Rat hepatocytes were isolated and purified by two-step *in situ* collagenase perfusion
101 according to the method of Seglen (Seglen, 1975). In brief, under sodium pentobarbital
102 (45 mg/kg, i.p.) anesthesia, cannulation to the portal vein was performed. Then, the liver
103 was refluxed in Ca²⁺-free Hanks as perfusion buffer for 10 min at 37 °C. Next, the solution
104 was changed to perfusion buffer containing 0.025% collagenase Type II (Worthington
105 Biochemical Corp., Freehold, NJ, USA.) and 5.0 mM CaCl₂ refluxed for 10-11 min.
106 Isolated hepatocytes were used at more than 96% cell viability by trypan blue exclusion.
107 Hepatocytes (3.3×10^4 cells/cm²) were plated and cultured for 3 h with Williams' medium
108 E (Sigma-Aldrich Co., St. Louis, MO, USA) containing newborn bovine serum (Thermo
109 Fisher Scientific, Inc., Waltham, MA, USA.) and 10⁻¹⁰ M dexamethasone. After a 3-h
110 attachment period, the medium was exchanged to serum-free medium with various
111 reagents. The reagents added to hepatocytes were SAC, alliin, allicin (Tokyo Chemical
112 Industry Co., Tokyo, Japan), and growth-related signal-transducing factor inhibitors or
113 monoclonal antibodies. The inhibitors used were AG538 (Blum et al., 2003), LY294002
114 (Vlahos et al., 1994), PD98059 (Li et al., 2008), rapamycin (Dixon et al., 1999),
115 TG101209 (Pardanani et al., 2007), SH-4-54 (Haftchenary et al., 2013), and U-73122
116 (Thompson et al., 1991), which were obtained from Sigma-Aldrich Co. The monoclonal
117 antibodies used were against growth hormone receptor, insulin-like growth factor (IGF)-
118 I receptor, epidermal growth factor (EGF) receptor, and hepatocyte growth factor (HGF)
119 receptor, which were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).

120

121 **2.3 Counting the number of nuclei and hepatocytes**

122 The cell proliferation effect of SAC was evaluated by measuring the number of
123 hepatocyte nuclei using a slight modification of the method of Nakamura (Nakamura et
124 al., 1983). Briefly, hepatocyte nuclei isolated in 0.1% Triton X-100 containing 0.1 M citric
125 acid were stained with 0.3% trypan blue, and the number of nuclei was measured with a
126 hemocytometer. In this study, the cell proliferation effect was evaluated by measuring the
127 number of nuclei rather than the number of cells, because the attachment between plates
128 or cell-cell contact is tight in hepatocytes, and a single cell cannot be isolated
129 quantitatively.

130 The numbers of total hepatocytes per 0.01 cm² (namely, $\times 10^2$ cells/cm²) were counted
131 in a phase-contrast microscopic image. The values were measured from cells in
132 microscopic images taken at any three locations, and the average was taken as one
133 example.

134

135 **2.4 RNA extraction and quantification of *c-Myc*, *c-Fos*, and *cyclin B1* mRNA**

136 The mRNA expression levels of *c-Myc*, *c-Fos*, and *cyclin B1* in cultured hepatocytes
137 were quantified using the TaqMan assay. The total RNA of the cultured hepatocytes was
138 extracted with Direct-zol RNA Miniprep (Zymo Research Co., Tustin, CA, USA), and
139 then a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City,
140 CA, USA) was used for reverse transcription from the obtained RNA to cDNA. Next, 5
141 $\mu\text{g}/\mu\text{L}$ of cDNA mixed with Fast Advanced Master Mix (Applied Biosystems) and
142 TaqMan probe (*c-Myc*, *c-Fos*, *cyclin B1*, or glyceraldehyde 3-phosphate dehydrogenase
143 [*GAPDH*]) were put in a StepOne Real-Time PCR System (Thermo Fisher Scientific,
144 Inc.), and each mRNA expression level was determined. *GAPDH* mRNA expression

145 levels were used as an endogenous control, and relative mRNA expression levels were
146 calculated by the $\Delta\Delta C_t$ method (Livak and Schmittgen, 2001).

147

148 **2.5 Detection of the S-phase and the G₀/G₁-phase of the cell cycle**

149 DNA synthesis was determined by detecting the S-phase of the cell cycle. The S-phase
150 and the G₀/G₁-phase in cultured hepatocytes were measured with a Muse™ cell analyzer,
151 using a slight modification to the manufacturer's instructions (Merck Millipore,
152 Darmstadt, Germany) (Kimura et al., 2014). Briefly, nuclei were isolated by lysing
153 hepatocytes as described in section 2.3 above. The isolated nuclei were mixed with 5%
154 propidium iodide (Fujifilm Wako Pure Chemical Corp., Tokyo, Japan) and incubated for
155 15 min. The Muse™ cell analyzer is a cell analysis apparatus-based flow cytometer, and
156 the cell cycle, including the S-phase or G₀/G₁-phase, was measured by this device.

157

158 **2.6 Measurement of phosphorylated p125 kDa Janus kinase (JAK) 2, p95 kDa 159 receptor tyrosine kinase (RTK), and p44/42 kDa MAP kinase (ERK1/2)**

160 Phosphorylated p125 kDa JAK2, p95 kDa RTK, and p44/42 kDa MAPK (ERK1/2)
161 were measured by Western blotting analysis (Kurihara et al., 2021b; Towbin et al., 1979).
162 Briefly, the cultured hepatocytes were lysed by Lysis buffer (Cell Signaling Technology,
163 Inc., Danvers, MA, USA) and centrifuged, and then the supernatant was mixed with a
164 Laemmli sample buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The protein
165 samples (30 μ g/lane) were divided by polyacrylamide gel electrophoresis and transferred
166 to a PVDF transfer membrane (PerkinElmer, Inc., Waltham, MA, USA). Next, they were
167 immunoblotted with monoclonal antibodies against phosphorylated p125 kDa JAK2, p95
168 kDa RTK, or ERK1/2 (Cell Signaling Technology). The phosphorylated ERK1/2

169 antibody was diluted 2000-fold, and the phosphorylated p125 kDa JAK2 and p95 kDa
170 RTK antibodies were diluted 1000-fold. After incubation with HRP-labeled secondary
171 antibody (Cell Signaling Technology), the blot was detected by Western Lightning Plus-
172 ECL (PerkinElmer, Inc.). Emission intensity was quantified by ChemiDoc Touch MP
173 (Bio-Rad Laboratories, Inc.). Phosphorylated p125 kDa JAK2, p95 RTK, or ERK1/2
174 activity ratios were calculated by dividing the respective expression levels (p125 kDa
175 JAK2, p95 kDa RTK, or ERK1/2 antibodies [Cell Signaling Technology]) by the total
176 activity. Each of these antibodies was diluted 1000-fold.

177

178 **2.7 Statistical analysis**

179 Values are shown as means \pm standard error of the mean (SEM) of three separate
180 experiments. For comparison with the control, Dunnett's test was performed, and the
181 significance level was defined as 5%.

182

183 **3. Results**

184 **3.1 Time- and dose-dependent cell proliferation effects of SAC and its analogs on** 185 **cultured hepatocytes**

186 The cell proliferation effects of SAC and its analogs (alliin or allicin) were investigated
187 in cultured hepatocytes. Hepatocytes attached to the plate and exchanged for serum-free
188 medium were cultured with SAC, alliin, allicin, or a combination of SAC with a selective
189 JAK2 inhibitor TG101209 or a selective signal transducer and activator of transcription
190 3/5 (STAT3/5) inhibitor SH-4-54. Fig. 2 shows a phase-contrast microscopic image of
191 cultured hepatocytes for 5 h. It can be confirmed that the number of SAC-stimulated
192 hepatocyte nuclei was greater than control (medium alone) (Fig. 2A, B). As shown in Fig.

193 2G, the number of total hepatocytes per field of view (per 0.01 cm²[×10² cells/cm²]) under
194 the microscope in the control treatment (medium only) was 309 ± 15. In contrast, the
195 number of total hepatocytes stimulated with 10⁻⁶ M SAC was 407 ± 19, which was a
196 significant increase of approximately 1.32-fold compared to the control (Fig. 2G). The
197 correlation coefficient between the number of hepatocytes and nuclei stimulated by SAC
198 was 0.95 (Fig.2.H). On the other hand, no increase in the number of hepatocytes was
199 observed with alliin or allicin stimulation (Fig. 2C, D and G). In addition, the number of
200 total hepatocytes treated with SAC and TG101209 was significantly reduced to control
201 levels, but no reduction in the number of hepatocytes was observed in the combination of
202 SAC with SH-4-54 (Fig. 2E-G).

203 Next, the number of hepatocyte nuclei was measured to assess the time- and dose-
204 dependent proliferative effects of SAC or its analogs (Fig. 3A, B). As shown in Fig. 3A,
205 SAC-stimulated hepatocyte nuclei were observed to proliferate depending on the culture
206 time. In 10⁻⁶ M SAC-treatment, a significantly higher number of nuclei on cultured
207 hepatocytes was observed at about 4 h, peaked at approximately 5 h, and then continued
208 for up to 21 h. In contrast, allicin and alliin did not show a significant increase in
209 hepatocyte nuclei (Fig. 3A). Next, fixing the culture time at 5 h in serum-free culture,
210 effects of SAC or its derivatives at concentrations of 10⁻¹⁰ to 10⁻⁵ M on the number of
211 hepatocyte nuclei were examined. SAC-stimulated hepatocyte nuclei were increased
212 dose-dependently and plateaued at 10⁻⁶ M, with the 50% effective concentration (EC₅₀)
213 value of 8.58 × 10⁻⁸ M. In contrast, no hepatocyte proliferation effect of alliin or allicin
214 was observed in the range of 10⁻¹⁰ to 10⁻⁵ M (Fig. 3B).

215

216 **3.2 Effects of SAC and its analogs on *c-Myc*, *c-Fos*, and *cyclin B1* mRNA expression**

217 levels in cultured hepatocytes

218 It is known that oncogenes such as *c-Myc* and *c-Fos* are involved in cultured hepatocyte
219 proliferation and liver regeneration (Fausto, 2000). The StepOne Real-Time PCR System
220 was used to investigate whether *c-Myc* and *c-Fos* mRNAs were expressed in hepatocytes
221 stimulated with SAC and its analogs. Fig. 4A shows the time course associated with *c-*
222 *Myc* mRNA expression levels in hepatocytes stimulated with SAC and its analogs. The
223 expression level of *c-Myc* mRNA was significantly increased in SAC-stimulated
224 hepatocytes. The peak was observed 1 h after addition of SAC (10^{-6} M), and the
225 expression level increased approximately 1.62-fold compared with time 0. On the other
226 hand, stimulation with alliin (10^{-6} M) or allicin (10^{-6} M) did not significantly increase *c-*
227 *Myc* mRNA expression levels. Fig. 4B shows *c-Fos* mRNA expression levels in SAC- or
228 its analog-stimulated hepatocytes. The *c-Fos* mRNA expression levels showed a time
229 course similar to those of *c-Myc*, and the increase was approximately 1.85-fold in SAC-
230 stimulated hepatocytes 1 h after stimulation (Fig. 4B).

231 In addition, mRNA expression levels of *cyclin B1* were measured as a G₂/M phase
232 marker in SAC or analog-stimulated hepatocytes. As shown in Fig. 4C, *cyclin B1* mRNA
233 expression levels in SAC (10^{-6} M)-stimulated hepatocytes began to increase at 3 h and
234 peaked at 3.5 to 4 h. At the peak times, the proportion of SAC-induced *cyclin B1* was
235 significantly increased by approximately 1.72-fold compared to controls (Fig.4C). Alliin
236 (10^{-6} M) or allicin (10^{-6} M) did not show a significant increase in *cyclin B1* mRNA
237 expression in hepatocytes (Fig.4C).

238

239 3.3 Time course effects of SAC and its analogs on S- and G₀/G₁-phase progression in 240 cultured hepatocytes

241 To investigate whether SAC promotes DNA synthesis in cultured hepatocytes, the S-
242 phase in the cell cycle of hepatocytes stimulated with SAC and its analogs was measured.
243 As shown in Fig. 5A, the proportion of S-phase of SAC (10^{-6} M)-stimulated hepatocytes
244 was significantly higher over 3 to 5 h compared to controls. In contrast, alliin (10^{-6} M)-
245 or allicin (10^{-6} M)-stimulated hepatocytes did not show an effect on the proportion of S-
246 phase (Fig. 5A). Furthermore, the proportion of hepatocyte nuclei for the G₀/G₁-phase
247 further decreased significantly in SAC (10^{-6} M) than in control at 3 and 4 h (Fig. 5B).

248

249 **3.4 Effects of monoclonal antibodies against growth factor receptors on SAC-** 250 **induced hepatocyte proliferation**

251 To investigate whether SAC showed a cell proliferation effect via growth factor
252 receptors expressed in cultured hepatocytes, the number of nuclei and the progression of
253 the S-phase of SAC-stimulated hepatocytes in the presence of monoclonal antibodies to
254 growth factor receptors associated with cell proliferation were measured. As shown in
255 Fig. 6A, B, SAC-stimulated progression of the S-phase and increase in hepatocellular
256 nuclei were completely suppressed by monoclonal antibodies to GH receptor and IGF-I
257 receptor, respectively. In contrast, monoclonal antibodies against HGF and EGF receptors
258 did not suppress the SAC-induced hepatocyte proliferation (Fig. 6A, B).

259

260 **3.5 Effects of SAC on hepatocyte proliferation in the presence of specific signal** 261 **transduction factor inhibitors**

262 Next, to investigate intracellular signaling pathways associated with SAC-induced cell
263 proliferation and DNA synthesis, the number of nuclei and progression of S-phase of
264 SAC-stimulated hepatocytes in the presence of specific signaling factor inhibitors

265 associated with cell proliferation were measured. Fig. 7A, B show that the hepatocyte
266 proliferation effects of SAC were completely inhibited to control level by TG101209, a
267 selective PLC inhibitor (U-73122), a selective IGF-I RTK inhibitor (AG538), a selective
268 phosphoinositide 3-kinase inhibitor (LY294002), a selective MAPK/ERK kinase (MEK)
269 inhibitor (PD98059), and a selective mammalian target of rapamycin (mTOR) inhibitor
270 (rapamycin). On the other hand, SH-4-54 did not inhibit the SAC-induced hepatocyte
271 proliferation (Fig. 7A, B).

272

273 **3.6 Time courses of the effects of SAC on p125 kDa JAK2, p95 kDa IGF-I RTK, and** 274 **ERK1/2 phosphorylation in cultured hepatocytes**

275 JAK2, IGF-I RTK, and ERK1/2 phosphorylation patterns of the SAC-stimulated
276 hepatocytes were measured by Western blot analysis. Fig. 8A shows that phosphorylated
277 p125 kDa JAK2 increased sharply after the addition of SAC and peaked at 5 min; p125
278 kDa JAK2 phosphorylation activity by SAC at the peak was approximately 2.3-fold the
279 activity ratio compared to the control. Then, the phosphorylation activities began to
280 decrease to control levels after 30 and 60 min of culture (Fig. 8A). Phosphorylation by
281 SAC of IGF-I RTK and ERK2 was observed later than that of JAK2, with peaks 20 and
282 30 min after SAC addition, respectively. However, no increase in ERK1 phosphorylation
283 was observed with SAC (Fig. 8B, C).

284

285 **3.7 Effects of specific signal transduction factor inhibitors on phosphorylation of** 286 **JAK2, p95 kDa IGF-I RTK, and ERK2 induced by SAC**

287 Next, the effects of specific inhibitors of growth-related signal transducers on JAK2,
288 IGF-I RTK, and ERK2 phosphorylated by SAC were investigated. Fig. 9 shows that SAC-

289 induced JAK2 phosphorylation was suppressed only by TG101209 (Fig. 9A). SAC-
290 induced IGF-I RTK phosphorylation was suppressed not only by TG101209, but also by
291 U-73122 and AG538 (Fig. 9B). SAC-induced ERK2 phosphorylation was suppressed by
292 LY294002 and PD98059, in addition to the above inhibitors (Fig. 9C). SH-4-54 or
293 rapamycin did not affect SAC-induced phosphorylation of both IGF-I RTK and ERK2
294 (Fig. 9A-C).

295

296 **4. Discussion**

297 In our previous studies, we demonstrated that SAC accelerated liver regeneration and
298 promoted cell proliferation *in vivo* in two-thirds partially hepatectomized rats (Kurihara
299 et al., 2020). The aim of this study was to examine the mechanism of the proliferative
300 effect of SAC compared to its analogues in primary cultures of adult rat hepatocytes *in*
301 *vitro*.

302 Fig. 2 showed that SAC, but not alliin or allicin, significantly increased the number of
303 hepatocytes at 5 h of culture. These results showed that there was a close correlation
304 between the increase in the number of cells and the number of nuclei shown in Figs. 2H,
305 3, and 7. Furthermore, the effects of SAC on hepatocyte numbers were completely
306 suppressed by TG101209, but not SH-4-54. The results suggest that the effects of SAC
307 are mediated by JAK2, but not STATs.

308 *c-Myc* and *c-Fos* are proto-oncogenes expressed during early liver regeneration and are
309 involved in the transition from the G₀ phase to the G₁-phase in the cell cycle of
310 regenerated hepatocytes (Corral et al., 1988; Morello et al., 1990). Accordingly, since
311 SAC significantly increased mRNA expression levels of *c-Myc* and *c-Fos*, SAC can
312 advance the G₀ phase cells to G₁-phase (Fig. 4A and B). In addition, since SAC also

313 increased mRNA expression levels of *cyclin B1*, SAC promoted progression to S- and
314 G₂/M-phases in cultured hepatocytes (Fig. 4C, 5).

315 Rapid cell proliferation effects on hepatocytes have been demonstrated not only with
316 SAC, but also with growth factors such as HGF and IGF-I (Kimura and Ogihara, 1998,
317 1997). It has been shown that the proliferative effects of growth factors in cultured
318 hepatocytes are affected by cell density and dexamethasone. Nakamura *et al.* reported
319 that incorporation of [³H]-thymidine into the nucleus (as a DNA synthesis index) in
320 hepatocytes treated with epidermal growth factor and insulin was faster at low cell density
321 (2.5×10^4 cells/cm²) than at high cell density (1.0×10^5 cells/cm²) (Nakamura *et al.*, 1983).
322 Furthermore, we demonstrated that the hepatocellular proliferation effect of HGF was
323 suppressed depending on the dose of dexamethasone (10^{-10} - 10^{-7} M) (Kimura *et al.*, 2011).
324 The rapid cell proliferation effect of SAC may be affected by the cell density (3.3×10^4
325 cells/cm²) and dexamethasone (10^{-10} M) concentration in the culture conditions of this
326 study.

327 Alliin has a structure in which oxygen is added to the sulfur part of SAC, and its
328 structure is very similar to SAC (Fig. 1). Not only SAC, but also alliin and its metabolite,
329 allicin, have antioxidant effects based on the removal of reactive oxygen or activation of
330 the Nrf2-Keap pathway (Chung, 2006; Li *et al.*, 2012b, 2012a). In other words, the results
331 in Figs. 2 to 5 imply that the proliferative effect of SAC on hepatocytes does not go
332 through the Nrf2-Keap pathway in cultured hepatocytes. In addition, we have
333 demonstrated that antioxidants such as isoascorbic acid and vitamin E do not cause
334 hepatocyte proliferation (Moteki *et al.*, 2012). These results suggest that the hepatocyte
335 proliferation effect of SAC proceeds by a mechanism different from the antioxidant effect.

336 To analyze the target of SAC and the signal transduction pathways, effects of some

337 monoclonal antibodies against growth factors on SAC-induced hepatocyte proliferation
338 were examined. Fig. 6 shows that SAC-induced progression of the S-phase and the
339 number of nuclei in hepatocytes were completely suppressed by monoclonal antibodies
340 to the GH receptor and IGF-I receptor. In the past, we demonstrated that GH secretes IGF-
341 I by stimulation of the GH receptor/JAK2/PLC pathway, and that the secreted IGF-I
342 promotes hepatocyte DNA synthesis and cell proliferation via the IGF-I
343 RTK/PI3K/ERK2/mTOR pathway in primary cultures of adult rat hepatocytes (Kurihara
344 et al., 2021b, 2021a). Based on these results, we hypothesized that SAC promotes cell
345 proliferation via the GH signaling pathway. In support of this notion, the hepatocyte
346 proliferation effect of SAC was completely suppressed by inhibitors related to the
347 JAK2/PLC and IGF-I signaling pathways (Fig. 7). In addition, as shown in Fig. 8, Western
348 blot analysis confirmed that SAC phosphorylated p125 kDa JAK2, p95 kDa RTK (i.e.,
349 IGF-I RTK), and ERK2 in cultured hepatocytes. The ERK2, but not ERK1,
350 phosphorylation-enhancing effect of SAC was also observed in the remaining liver in
351 SAC-treated partially hepatectomized rats (Kurihara et al., 2020). Fig. 8 shows that the
352 peak of SAC-induced JAK2 phosphorylation was faster than that of SAC-induced RTK
353 and ERK2 phosphorylation. Furthermore, Fig. 9 shows that SAC-induced RTK
354 phosphorylation was suppressed by TG101209 and U-73122. These results indicate the
355 presence of IGF-I RTK downstream of JAK2/PLC in the SAC-induced hepatocyte
356 proliferation signaling pathway. It has been reported that JAK1, which is one of the JAK
357 family, interacts with PLC (Chang et al., 2004; Clark et al., 2014). However, TG101209,
358 which inhibited SAC-induced PLC, has high specificity for JAK2 and low affinity for
359 JAK1 and JAK3 (Pardanani et al., 2007). Therefore, the interaction of JAK with PLC
360 may be mainly mediated by JAK2. On the other hand, LY294002 and PD98059

361 suppressed SAC-induced ERK2 phosphorylation, but not SAC-induced p95 IGF-I RTK
362 phosphorylation. In contrast, rapamycin did not suppress both SAC-induced RTK and
363 ERK2 (Fig. 9). These results indicate that PI3K and MEK are upstream elements of ERK2,
364 and mTOR is a downstream element of ERK2. Taken together, these results support the
365 notion that SAC activates the IGF-I RTK/PI3K/MEK/ERK2/mTOR pathway expressed
366 in cultured hepatocytes. In addition, we have previously demonstrated that SAC
367 stimulates autocrine secretion of IGF-I (Moteki et al., 2022).

368 In conclusion, the results of the present study showed that SAC rapidly stimulated
369 proliferation in primary cultures of adult rat hepatocytes, and that the hepatocyte
370 proliferation effect of SAC was based on activation of the GH receptor/JAK2/PLC
371 pathway followed by activation of the IGF-I RTK/PI3K/ERK2/mTOR pathway.

372

373 **CRedit authorship contribution statement**

374 Hajime Moteki participated in conducting all the experiments in this study and writing a
375 draft of this manuscript. Mitsutoshi Kimura participated in supervising the planning and
376 execution of the study. Masahiko Ogihara edited the manuscript and managed the project
377 for this research. The final manuscript was approved by all authors.

378

379 **Declarations of interest:** none

380

381 **Acknowledgment**

382 This work was supported by JSPS KAKENHI grant number 20K16011.

383

384

385 **References**

- 386 Amagase, H., Petesch, B.L., Matsuura, H., Kasuga S, Itakura, Y., 2001. Intake of garlic
387 and its bioactive components. *J. Nutr.* 131, 955S-962S.
- 388 Blum, G., Gazit, A., Levitzki, A., 2003. Development of New Insulin-like Growth Factor-
389 1 Receptor Kinase Inhibitors Using Catechol Mimics. *J. Biol. Chem.* 278, 40442–
390 40454.
- 391 Borlinghaus, J., Albrecht, F., Gruhlke, M.C., Nwachukwu, I.D., Slusarenko, A.J., 2014.
392 Allicin: Chemistry and biological properties. *Molecules* 19, 12591–12618.
- 393 Chang, Y.J., Holtzman, M.J., Chen, C.C., 2004. Differential Role of Janus Family
394 Kinases (JAKs) in Interferon- γ -Induced Lung Epithelial ICAM-1 Expression:
395 Involving Protein Interactions between JAKs, Phospholipase C γ , c-Src, and STAT1.
396 *Mol. Pharmacol.* 65, 589–598.
- 397 Chung, L.Y., 2006. The antioxidant properties of garlic compounds: allyl cysteine, alliin,
398 allicin, and allyl disulfide. *J. Med. Food.* 9, 205–213.
- 399 Clark, J.D., Flanagan, M.E., Telliez, J.B., 2014. Discovery and development of Janus
400 kinase (JAK) inhibitors for inflammatory diseases. *J. Med. Chem.* 57, 5023–5038.
- 401 Colín-González, A.L., Ali, S.F., Túnez, I., Santamaría, A., 2015. On the antioxidant,
402 neuroprotective and anti-inflammatory properties of S-allyl cysteine: An update.
403 *Neurochem. Int.* 89, 83–91.
- 404 Colín-González, A.L., Santana, R.A., Silva-Islas, C.A., Chánez-Cárdenas, M.E.,
405 Santamaría, A., Maldonado, P.D., 2012. The antioxidant mechanisms underlying the
406 aged garlic extract- and S-allylcysteine-induced protection. *Oxid. Med. Cell. Longev.*
407 2012.
- 408 Corral, M., Paris, B., Guguen-Guillouzo, C., Corcos, D., Kruh, J., Defer, N., 1988.

409 Increased expression of the N-myc gene during normal and neoplastic rat liver
410 growth. *Exp. Cell Res.* 174, 107–115.

411 Dixon, M., Agius, L., Yeaman, S.J., Day, C.P., 1999. Inhibition of rat hepatocyte
412 proliferation by transforming growth factor β and glucagon is associated with
413 inhibition of ERK2 and p70 S6 kinase. *Hepatology* 29, 1418–1424.

414 Fausto, N., 2000. Liver regeneration. *J. Hepatol.* 32, 19–31.

415 Fausto, N., Campbell, J.S., Riehle, K.J., 2006. Liver regeneration. *Hepatology* 43, S45-
416 53.

417 Haftchenary, S., Luchman, H.A., Jouk, A.O., Veloso, A.J., Page, B.D.G., Cheng, X.R.,
418 Dawson, S.S., Grinshtein, N., Shahani, V.M., Kerman, K., Kaplan, D.R., Gri, C.,
419 Aman, A.M., Al-awar, R., Weiss, S., Gunning, P.T., 2013. Promising Route for
420 Treating Glioblastoma. *ACS Med. Chem. Lett.* 705, 1102–1107.

421 Kalayarasan, S., Sriram, N., Sureshkumar, A., Sudhandiran, G., 2008. Chromium (VI)-
422 induced oxidative stress and apoptosis is reduced by garlic and its derivative S-
423 allylcysteine through the activation of Nrf2 in the hepatocytes of Wistar rats. *J. Appl.*
424 *Toxicol.* 28, 908–919.

425 Kim, J.M., Chang, N., Kim, W.K., Chun, H.S., 2006. Dietary S-Allyl-L-cysteine reduces
426 mortality with decreased incidence of stroke and behavioral changes in stroke-prone
427 spontaneously hypertensive rats. *Biosci. Biotechnol. Biochem.* 70, 1969–1971.

428 Kimura, M., Moteki, H., Ogihara, M., 2014. Involvement of endogenous transforming
429 growth factor- α in signal transduction pathway for interleukin-1 β -induced
430 hepatocyte proliferation. *Eur. J. Pharmacol.* 745, 223–233.

431 Kimura, M., Moteki, H., Ogihara, M., 2011. Inhibitory effects of dexamethasone on
432 hepatocyte growth factor-induced DNA synthesis and proliferation in primary

433 cultures of adult rat hepatocytes. *J. Pharmacol. Sci.* 115, 390–398.

434 Kimura, M., Ogihara, M., 1998. Effects of insulin-like growth factor I and II on DNA
435 synthesis and proliferation in primary cultures of adult rat hepatocytes. *Eur. J.*
436 *Pharmacol.* 354, 271–281.

437 Kimura, M., Ogihara, M., 1997. Proliferation of adult rat hepatocytes by hepatocyte
438 growth factor is potentiated by both phenylephrine and metaproterenol. *J Pharmacol*
439 *Exp Ther* 282, 1146–1154.

440 Kurihara, K., Moteki, H., Kimura, M., Ogihara, M., 2021a. Autocrine secretion of insulin-
441 like growth factor-I mediates growth hormone-stimulated DNA synthesis and
442 proliferation in primary cultures of adult rat hepatocytes. *Eur. J. Pharmacol.* 891,
443 173753.

444 Kurihara, K., Moteki, H., Natsume, H., Ogihara, M., Kimura, M., 2020. The enhancing
445 effects of s-allylcysteine on liver regeneration are associated with increased
446 expression of mrnas encoding igf-1 and its receptor in two-thirds partially
447 hepatectomized rats. *Biol. Pharm. Bull.* 43, 1776–1784.

448 Kurihara, K., Moteki, H., Ogihara, M., Kimura, M., 2021b. Growth hormone signaling
449 pathway leading to the induction of dna synthesis and proliferation in primary
450 cultured hepatocytes of adult rats. *J. Pharm. Pharm. Sci.* 24, 1–15.

451 Li, X., Huang, Y., Jiang, J., Frank, S.J., 2008. ERK-dependent threonine phosphorylation
452 of EGF receptor modulates receptor downregulation and signaling. *Cell. Signal.* 20,
453 2145–2155.

454 Li, X.H., Li, C.Y., Lu, J.M., Tian, R.B., Wei, J., 2012a. Allicin ameliorates cognitive
455 deficits ageing-induced learning and memory deficits through enhancing of Nrf2
456 antioxidant signaling pathways. *Neurosci. Lett.* 514, 46–50.

457 Li, X.H., Li, C.Y., Xiang, Z.G., Hu, J.J., Lu, J.M., Tian, R.B., Jia, W., 2012b. Allicin
458 ameliorates cardiac hypertrophy and fibrosis through enhancing of nrf2 antioxidant
459 signaling pathways. *Cardiovasc. Drugs Ther.* 26, 457–465.

460 Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-
461 time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods* 25, 402–408.

462 Michalopoulos, G.K., DeFrances, M.C., 1997. Liver Regeneration. *Science.* 276, 5360–
463 5366.

464 Morello, D., Lavenu, A., Babinet, C., 1990. Differential regulation and expression of jun,
465 c-fos and c-myc proto-oncogenes during mouse liver regeneration and after
466 inhibition of protein synthesis. *Oncogene* 5, 1511–1519.

467 Morrison, D.K., 2012. MAP kinase pathways. *Cold Spring Harb. Perspect. Biol.* 4, 1–6.

468 Moteki, H., Shimamura, Y., Kimura, M., Ogihara, M., 2012. Signal transduction pathway
469 for l-ascorbic acid- and l-ascorbic acid 2-glucoside-induced DNA synthesis and cell
470 proliferation in primary cultures of adult rat hepatocytes. *Eur. J. Pharmacol.* 683,
471 276–284.

472 Moteki, H., Ogihara, M., Kimura, M., 2022. S-Allyl-L-cysteine promotes cell
473 proliferation by stimulating growth hormone receptor/janus kinase 2/phospholipase
474 C pathways and promoting insulin-like growth factor type-I secretion in primary
475 cultures of adult rat hepatocytes. *Biol. Pharm. Bull.* 45, 625-634

476 Nakamura, T., Tomita, Y., Ichihara, A., 1983. Density-dependent growth control of adult
477 rat hepatocytes in primary culture. *J. Biochem.* 94, 1029–1035.

478 Nam, S.M., Yoo, D.Y., Kim, W., Yoo, M., Kim, D.-W., Won, M.-H., Hwang, I.K., Yoon,
479 Y.S., 2011. Effects of S-Allyl-L-Cysteine on Cell Proliferation and Neuroblast
480 Differentiation in the Mouse Dentate Gyrus. *J. Vet. Med. Sci.* 37, 261–267.

481 Pardanani, A., Hood, J., Lasho, T., Levine, R.L., Martin, M.B., Noronha, G., Finke, C.,
482 Mak, C.C., Mesa, R., Zhu, H., Soll, R., Gilliland, D.G., Tefferi, A., 2007. TG101209,
483 a small molecule JAK2-selective kinase inhibitor potently inhibits
484 myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
485 *Leukemia* 21, 1658–1668.

486 Seglen, P.O., 1975. Preparation of isolated liver cells. *Meths Cell Biol.* 13, 29–83.

487 Sohn, C.W., Kim, H., You, B.R., Kim, M.J., Kim, H.J., Lee, J.Y., Sok, D.E., Kim, J.H.,
488 Lee, K.J., Kim, M.R., 2012. High temperature- and high pressure-processed garlic
489 improves lipid profiles in rats fed high cholesterol diets. *J. Med. Food* 15, 435–440.


490 Thompson, A.K., Mostafapour, S.P., Denlinger, L.C., Bleasdale, J.E., Fisher, S.K., 1991.
491 The aminosteroid U-73122 inhibits muscarinic receptor sequestration and
492 phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. A role for G(p) in
493 receptor compartmentation. *J. Biol. Chem.* 266, 23856–23862.

494 Towbin, H., Staehelin, T., Gordon, J., 1979. Electrophoretic transfer of proteins from
495 polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc*
496 *Natl Acad Sci U S A* 76, 4350–4354.

497 Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., 1994. A specific inhibitor of
498 phosphatidylinositol 3-kinase, 2-(4-morpholinyl)- 8-phenyl-4H-1-benzopyran-4-
499 one (LY294002). *J. Biol. Chem.* 269, 5241–5248.

500
501
502
503
504

1 Figures



2

3 Fig. 1 Biosynthetic pathway of SAC, alliin, and allicin in garlic

4

5

6

7

8


9

10



11

12

13




14



15




16 Fig. 2 Phase-contrast micrographs of hepatocytes cultured with SAC and its analogs for
17 5 h. As described in the Methods section, after a 3-h attachment period, hepatocytes (3.3
18 $\times 10^4$ cells/cm²) were cultured in serum-free medium containing SAC, alliin, or allicin
19 with growth-related signal-transducing factor inhibitors for 5 h. Photos are (A), control
20 (medium alone); (B), SAC (10^{-6} M); (C), alliin (10^{-6} M); (D), allicin (10^{-6} M); (E), SAC
21 (10^{-6} M) + TG101209 (10^{-6} M); (F), SAC (10^{-6} M) + SH4-54 (10^{-6} M); Scale bar, 200 μ m.
22 (G), Number of hepatocytes per field of view (per 0.01 cm²[$\times 10^2$ cells/ cm²]) under the
23 microscope. Values are shown as means \pm S.E.M. (n=3). ** (P<0.01) shows comparisons
24 with respective control. ## (P<0.01) shows comparisons with respective SAC treatment.
25 (H), Correlation between the number of hepatocytes and the number of nuclei. Open
26 circles (\circ), control (medium only, n=3); closed circles (\bullet), SAC (10^{-6} M) (n=3); closed
27 diamonds (\blacklozenge), SAC (10^{-6} M) + TG101209 (10^{-6} M) (n=3); closed squares (\blacksquare), SAC (10^{-6}
28 M) + SH4-54 (10^{-6} M) (n=3).

29
30
31
32
33
34
35
36




37

38 Fig. 3 Time- and dose-dependent cell proliferation effects of SAC and its analogs on
 39 cultured hepatocytes. As described in the Methods section, hepatocytes (3.3×10^4
 40 cells/cm²) attached to the plate were exchanged for serum-free medium and then SAC,
 41 alliin, or allicin was added. (A) Time-dependent cell proliferation effects of SAC (● 10^{-6}
 42 M), alliin (△ 10^{-6} M), or allicin (▼ 10^{-6} M) in cultured hepatocytes. The arrow shows the
 43 addition of the drugs. (B) Dose-dependent cell proliferative effects of SAC (● 10^{-10} - 10^{-6}
 44 M), alliin (△ 10^{-10} - 10^{-6} M), or allicin (▼ 10^{-10} - 10^{-6} M) on cell proliferation in cultured
 45 hepatocytes for 5 h of drug stimulation. Values are shown as means ± S.E.M. (n=3).
 46 *(P<0.05) and ** (P<0.01) show comparisons with respective control.



48 Fig. 4 Effects of SAC and its analogs on *c-Myc*, *c-Fos*, and *cyclin B1* mRNA expression
49 levels in cultured hepatocytes. The mRNA expression levels of *c-Myc*, *c-Fos*, and *cyclin*
50 *B1* in hepatocytes were quantified using the TaqMan assay, as described in the Methods
51 section. (A) *c-Myc*; (B) *c-Fos*; (C) *cyclin B1*. Control (○ medium alone), SAC (● 10^{-6} M),
52 alliin (△ 10^{-6} M), or allicin (▼ 10^{-6} M) were added at the arrow point. The value for
53 each sample was normalized to the GAPDH mRNA expression levels in each sample.
54 Values are shown as means ± S.E.M. (n=3). *(P<0.05) and ** (P<0.01) show comparison
55 with respective control.

56




57

58 Fig. 5 Time course of the effects of SAC and its analogs on S- and G₀/G₁-phase
 59 progression in cultured hepatocytes. S- and G₀/G₁-phases in SAC- (● 10⁻⁶ M), alliin- (Δ
 60 10⁻⁶ M), or allicin- (▼ 10⁻⁶ M) stimulated, as described in the Methods section. (A) Time
 61 course of the percentage in the S-phase. (B) Time course of the percentage in the G₀/G₁-
 62 phase. The arrow shows the addition of the drugs. Values are shown as means ± S.E.M.
 63 (n=3). *(P<0.05) and ** (P<0.01) show comparisons with respective control.

64

65



66

67 Fig. 6 Effects of monoclonal antibodies to growth factor receptors on SAC-induced
 68 hepatocyte proliferation. As described in the Methods section, hepatocytes (3.3×10^4
 69 cells/cm²) attached to the plate were exchanged for serum-free medium. Then,
 70 hepatocytes were cultured in the presence of SAC with or without growth-related signal-
 71 transducing inhibitors. S-phase progression (DNA synthesis [A]) and number of nuclei
 72 (cell proliferation [B]) were measured 5 h after SAC (10^{-6} M) was added. Monoclonal
 73 antibodies were to growth hormone receptor (anti-GHR mAb), insulin-like growth factor
 74 type-I receptor (anti-IGF-I R mAb), epidermal growth factor receptor (anti-EGFR mAb),

75 and hepatocyte growth factor receptor (anti-HGFR mAb). IgG (as a negative control).
76 The antibody concentrations are 100 ng/mL each. Values are shown as means \pm S.E.M.
77 (n=3). ** (P<0.01) shows comparisons with respective SAC treatment.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92


93

94

95

96

97



98

99 Fig. 7 Effects of SAC on hepatocyte proliferation in the presence of specific signal
 100 transduction factor inhibitors. After cell attachment and exchanging for serum-free
 101 medium as described in the Methods section, hepatocytes were cultured in the presence
 102 of SAC with or without growth-related signal-transducing factor inhibitors. S-phase
 103 progression (DNA synthesis [A]) and number of nuclei (cell proliferation [B]) were
 104 measured 5 h after SAC (10^{-6} M) was added. Inhibitors used were TG101209 (10^{-6} M),
 105 SH-4-54 (10^{-6} M), U-73122 (10^{-6} M), AG538 (10^{-7} M), LY294002 (10^{-7} M), PD98059

106 (10⁻⁶ M), and rapamycin (10 ng/mL). Values are shown as means ± S.E.M. (n=3).**

107 (P<0.01) shows comparisons with respective SAC treatment.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124




125

126

127

128

129



131 Fig. 8 Time course of the effects of SAC on p125 JAK2, p95 kDa IGF-I RTK, and ERK1/2
132 phosphorylation in cultured hepatocytes. Hepatocytes (3.3×10^4 cells/cm²) attached to
133 the plate were replaced with serum-free medium as described in the Methods section.
134 Phosphorylation of p125 JAK2, p95 kDa RTK, and ERK1/2 was determined by Western
135 blot analysis, as described in the Methods. (A) Percentages of phosphorylated p125 JAK2
136 (P-p125 kDa JAK2) / total p125 JAK (p125 kDa JAK2); (B) Percentages of
137 phosphorylated p95 RTK (P-p95 kDa RTK) / total p95 RTK (p95 kDa RTK); (C)
138 Percentages of phosphorylated ERK (P-ERK) 2 / total ERK (ERK) 2. Western blot images
139 are shown at the top of each graph. The arrow shows the addition of SAC (10^{-6} M). Values
140 are shown as means \pm S.E.M. (n=3). *(P<0.05) and ** (P<0.01) show comparisons with
141 respective control.

142

143

144

145

146

147

148

149




150

151

152

153

154



156 Fig. 9 Effects of specific signal transduction factor inhibitors on p125 JAK2, p95 kDa
157 IGF-I RTK, and ERK2 phosphorylation induced by SAC. After cell attachment and
158 exchanging for serum-free medium as described in the Methods, hepatocytes were
159 cultured in the presence of SAC with or without growth-related signal-transducing
160 inhibitors. Phosphorylation of p125 JAK2, p95 kDa RTK, and ERK1/2 was determined
161 by Western blot analysis, as described in the Methods. (A) Phosphorylation of p125 kDa
162 JAK2 5 min after SAC (10^{-6} M) stimulation. (B) Phosphorylation of p95 kDa RTK 20
163 min after SAC (10^{-6} M) stimulation. (C) Phosphorylation of ERK2 30 min after SAC (10^{-6}
164 M) stimulation. Western blot images are shown at the top of each graph. Inhibitors used
165 were TG101209 (10^{-6} M), SH-4-54 (10^{-6} M), U-73122 (10^{-6} M), AG538 (10^{-7} M),
166 LY294002 (10^{-7} M), PD98059 (10^{-6} M), and rapamycin. Values are shown as means \pm
167 S.E.M. (n=3).** (P<0.01) shows comparisons with respective SAC treatment.

168

169

170

171

172

173

174

175

176

177

CRedit Author Statement

Title of Manuscript:

Cell proliferation effects of *S*-allyl-L-cysteine are associated with phosphorylation of Janus kinase 2, insulin-like growth factor type-I receptor tyrosine kinase, and extracellular signal-regulated kinase 2 in primary cultures of adult rat hepatocytes.

Hajime Moteki: participated in conducting all the experiments in this study and writing a draft of this manuscript. **Mitsutoshi Kimura:** participated to supervise the planning and execution of the study. **Masahiko Ogihara:** edited the manuscript and managed the project for this research. The final manuscript was approved by all authors.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: